Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Black participants represented only 3% of cancer clinical trial participants between 2013 and 2022, finds GlobalData

Diversity within pharmaceutical studies continues to be a problem across a wide variety of clinical trial sectors, with industry sponsors and pivotal studies particularly experiencing issues, says GlobalData. When looking specifically at oncology, the leading data and analytics company found that Black participants are severely underrepresented in these studies, only accounting for 3% of the […]
Read more

Pfizer’s discontinuation of emprumapimod following Phase III trial leaves an unmet need that pharmaceutical companies should aim to fill, says GlobalData

Based on an interim futility analysis of its global Phase III trial, REALM-DCM, Pfizer has ceased clinical trial development of its therapy emprumapimod. The drug was meant to target dilated cardiomyopathy (DCM)* patients whose condition was due to a lamin gene mutation**. According to GlobalData’s report, ‘Cardiomyopathies – Global Drug Forecast and Market Analysis to […]
Read more

Axsome Therapeutics’ Auvelity will experience strong uptake globally by 2029 and reach $1.3 billion sales, forecasts GlobalData

Following the news that Axsome Therapeutics’ Auvelity (dextromethorphan + bupropion) has been approved by the FDA for the treatment of major depressive disorder (MDD) in adults; Pippa Salter, Senior Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Auvelity’s rapid onset of action will provide a major breakthrough to the MDD […]
Read more

Growing investment in biotech startups likely to make CAR-T therapies affordable in India, says GlobalData

Biotech startups in India, which are focused on developing cell/gene (including CAR-T) therapies for the management and treatment of certain life-limiting illnesses that significantly affect the patient’s quality of life, are increasingly attracting investment from major pharmaceutical companies. This is likely to boost their research and production capabilities and eventually makes the therapies affordable to […]
Read more

Karuna’s KarXT could have a major competitive edge for schizophrenia treatment, says GlobalData

Karuna Therapeutics recently announced positive topline results from the Phase III EMERGENT-2 trial of KarXT (xanomeline + trospium chloride) in acutely psychotic hospitalized adult patients with schizophrenia. According to GlobalData, if KarXT continues to show success within the EMERGENT trial program as a monotherapy, as well as in the ongoing ARISE trial as an adjunctive to traditional antipsychotics, […]
Read more

Long-acting injectables remain under-utilized for schizophrenia in 7MM despite benefits, says GlobalData

Long-acting injectable (LAI) formulations of antipsychotics to treat patients diagnosed with schizophrenia remain under-utilized in the seven major markets (7MM*) due to the resistance surrounding the use of these products despite the benefits, says GlobalData, a leading data and analytics company. According to GlobalData, patients tend to continue oral antipsychotic treatment, and this results in […]
Read more

Coherus’ Cimerli to Fuel Competition in Anti-VEGF Biosimilar Market Within DME Space, says GlobalData

On August 2, the Food and Drug Administration (FDA) announced the approval of Coherus’ Cimerli (ranibizumab-eqrn; FYB201), which demonstrated efficacy and safety results parallel to its reference product, Roche’s Lucentis (ranibizumab). This approval is of paramount interest as Cimerli is the first anti-VEGF biosimilar in the Diabetic Macular Edema (DME) space to gain a 12-month […]
Read more

Improved irritability treatments and novel treatments for ASD core symptoms are most important unmet needs in ASD market in 7MM, finds GlobalData

Improved treatments options for irritability and novel treatments for core symptoms of autism spectrum disorder (ASD) are the most important unmet needs in the ASD market in the seven major markets (7MM*), finds GlobalData, a leading data and analytics company. A recent survey** by GlobalData has revealed that treatment options to target irritability and aggression […]
Read more

Diagnosed prevalent cases of primary myelofibrosis in China set to increase by 34.8% between 2021 and 2031, forecasts GlobalData

The diagnosed prevalent cases of primary myelofibrosis (PMF) in China are expected to increase by 34.8% between 2021­ and 2031, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Myelofibrosis Epidemiology Analysis and Forecast, 2021-2031’, notes that the major drivers for the spike in the diagnosed prevalent cases of PMF in China […]
Read more

Advancements in GA pipeline bring first wave of therapies closer to patients, says GlobalData

Following the results from Apellis Pharmaceuticals’ Phase III ‘DERBY and OAKS’ study of APL-2 and the post hoc analysis from IVERIC BIO’s Phase III GATHER 1 clinical trial for Zimura, which provided a positive outlook for geographic atrophy (GA) patients by demonstrating clinically significant reduction in lesion growth, leading data and analytics company GlobalData highlights […]
Read more

Monkeypox outbreak must be taken seriously by public health officials, as new methods of viral spread have recently emerged, says GlobalData

Following the news that the World Health Organization (WHO) has declared the monkeypox outbreak a Public Health Emergency of International Concern (PHEIC); Nancy Jaser, PharmD/MBA, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Recent changes to the mode of transmission and disease presentation of monkeypox in the current outbreak are […]
Read more

12-month diagnosed prevalent cases of schizophrenia across 7MM to reach 3.49 million in 2031, forecasts GlobalData

The 12-month diagnosed prevalent cases of schizophrenia are expected to increase from 3.40 million in 2021 to 3.49 million in 2031 across the seven major markets (7MM*), at an annual growth rate (AGR) of 0.26%, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Schizophrenia Epidemiology Analysis and Forecast, 2021-2031’, reveals that the […]
Read more

Homegrown SKYCovione will strengthen South Korea position in global COVID-19 vaccine industry, says GlobalData

SK Bioscience has recently announced that South Korea’s first homegrown COVID-19 vaccine ‘SKYCovione’ adjuvanted with GlaxoSmithKline’s pandemic adjuvant has been authorized by the Korean Ministry of Food and Drug Safety (KMFDS). This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines, says GlobalData, […]
Read more
1 … 43 44 45 46 47 … 108